Chemomab
chemomab.com
Actively hiring
Drug Discovery
Biotechnology
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
OrbiMed
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
OrbiMed Similar startupsby what they do, their industry and backers
Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological…
By unleashing the power of covalent chemistry, we can deliver superior small molecule medicines with enhanced therapeutic benefit.
Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related…
Streamline discovery with our integrated drug discovery platform, blending AI, physics-based tools, and wet lab for unparalleled…
Angitia is a clinical-stage biotechnology company focused on discovering and developing breakthrough therapeutics that address the key…
Explore the future of inhaled therapy for COPD with AirNexis's innovative AN01 dry powder inhaler designed for ease of use.
News
Chemomab stock gains on trial win (update) (NASDAQ:CMMB)
Chemomab Therapeutics (CMMB) stock falls as the company announces a private placement along with a Phase 2 trial win for its lead asset. Read more here.
Read more
Report
Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise
Read more
Report
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis - Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
Read more
Report
Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
--Chemomab Therapeutics Ltd., a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced publication of proteomic analyses that further d
Read more
Report
Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023
Read more
Report
Chemomab Presents Clinical Data from Investigator-Initiated Study Showing CM-101 Reduced Inflammatory and Fibrogenesis-Related Biomarkers in Patients with Severe Lung Injury Derived from Covid-19
/PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of...
Read more
Report